Files and links (2)
Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice2.27 MB
Published VersionCC BY V4.0, Open Access
Journal article
Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice
Annals of Nuclear Medicine, Vol.35(7), pp.811-822
2021
PMID: 33948902
Abstract
Objective:
The combination of two or more drugs with different mechanisms is a promising strategy for cancer treatment, and radioimmunotherapy (RIT) is a trending antitumor strategy. Radiotherapy (RT) can promote and activate antitumor immune effects, and immunotherapy can strengthen the effects of selective internal radiotherapy (SIRT); the RIT combination is synergistic and can overcome the adverse side effects of monotherapy. In this study, we developed a radioimmunoconjugate (RIC)—the iodine-131 (131I)-labeled caerin 1.1 peptide—to treat human anaplastic thyroid cancer (ATC).
Methods:
Antitumor activity of caerin 1.1 peptide was determined by MTT assay, plate colony formation and cell wound scratch assays, and the mechanism of the inhibition of carein 1.1 peptide on the growth of CAL-62 cells was identified by cell cycle and western blot. Then, we investigated the efficacy of the caerin 1.1 peptide as a single drug and the 131I-labeled caerin 1.1 peptide for ATC. H&E and TUNEL staining was performed to detect dead cells in the tumor tissue sections.
Results:
We found that caerin 1.1 arrested cells in the S phase to induce apoptosis and inhibited tumor growth to inhibit phosphorylation of Akt. In vivo, the iodine-131 (131I)-labeled caerin 1.1 peptide achieved better antitumor efficacy than radiotherapy alone and showed a good biosafety profile.
Conclusions:
Our study demonstrates for the first time that the iodine-131 (131I)-labeled caerin 1.1 peptide can inhibit CAL-62 tumor growth and migration. The iodine-131 (131I)-labeled caerin 1.1 peptide, which represents a radioimmunotherapy strategy based on the combination of SIRT with a peptide–drug conjugate, could provide a treatment means for the radical cure of ATC.
Details
- Title
- Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice
- Authors
- Ruoting Lin (Author) - Guangdong Pharmaceutical UniversityBowei Ma (Author) - First Affiliated Hospital of Guangzhou University of Chinese MedicineNa Liu (Author) - First Affiliated Hospital of Guangzhou University of Chinese MedicineLu Zhang (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTiantian He (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityXiongying Liu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTongsheng Chen (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityWenjuan Liu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityYongnan Liang (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTianfang Wang (Author) - University of the Sunshine Coast, Queensland, GeneCology Research Centre - LegacyGuoying Ni (Author) - University of the Sunshine Coast, Queensland, GeneCology Research Centre - LegacyXiaosong Liu (Author) - University of the Sunshine Coast, Queensland, GeneCology Research Centre - LegacyNing Yang (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityJinhe Zhang (Author) - General Hospital of the Southern Theatre Command (China)Jianwei Yuan (Corresponding Author) - Guangdong Pharmaceutical University
- Publication details
- Annals of Nuclear Medicine, Vol.35(7), pp.811-822
- Publisher
- Springer Japan KK
- Date published
- 2021
- DOI
- 10.1007/s12149-021-01618-3
- ISSN
- 1864-6433; 0914-7187
- PMID
- 33948902
- Copyright note
- © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- Organisation Unit
- School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99534608402621
- Output Type
- Journal article
Metrics
2 File views/ downloads
28 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Radiology, Nuclear Medicine & Medical Imaging
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites